Your browser doesn't support javascript.
loading
High-mobility group box 1 induces bone destruction associated with advanced oral squamous cancer via RAGE and TLR4.
Sakamoto, Yumi; Okui, Tatsuo; Yoneda, Toshiyuki; Ryumon, Shoji; Nakamura, Tomoya; Kawai, Hotaka; Kunisada, Yuki; Ibaragi, Soichiro; Masui, Masanori; Ono, Kisho; Obata, Kyoichi; Shimo, Tsuyoshi; Sasaki, Akira.
Afiliación
  • Sakamoto Y; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
  • Okui T; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan. Electronic address: pphz1rke@okayama-u.ac.jp.
  • Yoneda T; Department of Cellular and Molecular Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan.
  • Ryumon S; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
  • Nakamura T; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
  • Kawai H; Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
  • Kunisada Y; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
  • Ibaragi S; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
  • Masui M; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
  • Ono K; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
  • Obata K; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
  • Shimo T; Division of Reconstructive Surgery for Oral and Maxillofacial Region, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, Hokkaido, Japan.
  • Sasaki A; Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
Biochem Biophys Res Commun ; 531(3): 422-430, 2020 10 20.
Article en En | MEDLINE | ID: mdl-32800556
ABSTRACT
Bone destruction of maxillary and mandibular bone by invasive oral squamous cell cancer (OSCC) raises various problems in the management of patients, resulting in poor outcomes and survival. However, the mechanism behind bone destruction by OSCC remains unclear. High-mobility group box 1 (HMGB1), a highly conserved ubiquitous nuclear non-histone DNA-binding protein, has been demonstrated to be secreted by aggressive cancers and regulate osteoclastogenesis, a central player during bone destruction. We therefore reasoned that HMGB1 secreted by OSCCs contributes to bone destruction. Our results showed that HMGB1 is produced by human cell lines of OSCC and promotes osteoclastogenesis via up-regulation of the expression of receptor activator of nuclear factor kappa-Β ligand in osteoblasts and osteocytes, and consequently osteoclastic bone destruction in mice. Further, we found that these actions of HMGB1 are mediated via the receptor for advanced glycation end products and toll-like receptors. These findings suggest that HMGB1 of OSCC and its down-stream signal pathways are potential targets for the treatment of bone destruction associated with advanced OSCC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Huesos / Proteína HMGB1 / Receptor Toll-Like 4 / Receptor para Productos Finales de Glicación Avanzada / Carcinoma de Células Escamosas de Cabeza y Cuello / Neoplasias de Cabeza y Cuello Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans / Male Idioma: En Revista: Biochem Biophys Res Commun Año: 2020 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Huesos / Proteína HMGB1 / Receptor Toll-Like 4 / Receptor para Productos Finales de Glicación Avanzada / Carcinoma de Células Escamosas de Cabeza y Cuello / Neoplasias de Cabeza y Cuello Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans / Male Idioma: En Revista: Biochem Biophys Res Commun Año: 2020 Tipo del documento: Article País de afiliación: Japón
...